SCHEDULE: Octagon Capital Discloses 6.4% Stake in Palisade Bio

Octagon Capital Advisors LP, along with Octagon Investments Master Fund LP and Ting Jia, has reported a 6.4% beneficial ownership stake in Palisade Bio, Inc.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia (collectively, "Reporting Persons") have jointly filed a Schedule 13G.
• The Reporting Persons beneficially own 9,567,898 shares of Palisade Bio, Inc. Common Stock.
• This ownership represents 6.4% of the company's outstanding Common Stock.
• The percentage is calculated based on 149,003,210 Common Shares outstanding as of November 5, 2025, as reported in the Issuer's Form 10-Q filed on November 10, 2025.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Octagon Capital Advisors LP serves as the investment manager of Octagon Investments Master Fund LP, and Ting Jia is the managing member of Octagon Capital Advisors LP.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a new institutional investor taking a significant stake (6.4%) can be interpreted as a vote of confidence in Palisade Bio's prospects, even if the filing explicitly states no intent to influence control.

Positives

• A significant institutional investor, Octagon Capital Advisors LP, has taken a 6.4% stake in Palisade Bio, indicating potential confidence in the company's future.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Negatives

• No specific negative information is contained within this beneficial ownership report.

Risks

• No specific risks related to Palisade Bio's operations or financial health are disclosed in this Schedule 13G filing. The filing only reports beneficial ownership.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that a new significant stake by an institutional investor like Octagon Capital Advisors in a biotechnology company such as Palisade Bio can signal increased investor interest or a belief in the company's long-term potential, particularly in a sector often characterized by high R&D costs and binary clinical trial outcomes. Such filings are closely watched for shifts in institutional sentiment.

Comparison to Industry Standards

• This filing reports a beneficial ownership stake and does not contain performance metrics or operational results that can be directly compared to industry standards or specific comparable companies. The significance lies in the identity and size of the new institutional holder rather than operational performance.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor could potentially boost investor confidence and attract further investment, potentially leading to increased share price stability or appreciation.
• Management: While the filing states no intent to influence control, a large institutional holder may still engage with management, providing a level of oversight or strategic input.

Key Dates

Recommendation

The filing indicates a new significant institutional investor has taken a 6.4% stake in Palisade Bio, which is generally a positive signal as it suggests confidence from a professional investment entity. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial data to warrant a "buy" or "sell" recommendation. The "hold" recommendation reflects the positive signal of institutional interest without new fundamental information to change the investment thesis.

Keywords

Palisade Bio, PALI, Octagon Capital Advisors, Octagon Investments Master Fund, Ting Jia, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology